Published in final edited form as:

Eur J Nucl Med Mol Imaging. 2016 November ; 43(12): 2122–2130. doi:10.1007/s00259-016-3437-y.

Synthesis and preclinical evaluation of an Al¹⁸F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand

Stefano Boschi¹, Jason T. Lee², Seval Beykan³, Roger Slavik⁴, Liu Wei⁴, Claudio Spick⁴, Uta Eberlein³, Andreas K. Buck³, Filippo Lodi¹, Gianfranco Cicoria⁵, Johannes Czernin⁴, Michael Lassmann³, Stefano Fanti¹, and Ken Herrmann^{3,4}

¹Department of Nuclear Medicine, S.Orsola-Malpighi University Hospital, Via Massarenti 9, 40138 Bologna, Italy

²Crump Institute for Molecular Imaging, David Geffen School of Medicine at UCLA, Los Angeles, USA

³Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany

⁴Ahmanson Translational Imaging Division, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave. CHS AR-255, Los Angeles, CA 90095, USA

⁵Department of Medical Physics, S. Orsola-Malpighi University Hospital, Bologna, Italy

Abstract

Purpose—The aim of this study was to synthesize and preclinically evaluate an ¹⁸F-PSMA positron emission tomography (PET) tracer. Prostate-specific membrane antigen (PSMA) specificity, biodistribution, and dosimetry in healthy and tumor-bearing mice were determined.

Methods—Several conditions for the labeling of ¹⁸F-PSMA-11 via ¹⁸F-AlF-complexation were screened to study the influence of reaction temperature, peptide amount, ethanol volume, and

[✉]Ken Herrmann, KHerrmann@mednet.ucla.edu.

Stefano Boschi and Jason T. Lee contributed equally to this work.

Compliance with ethical standards

Ethical approval Animal studies were approved by the UCLA Animal Research Committee and were carried out according to the guidelines of the Division of Laboratory Animal Medicine at UCLA. All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. This article does not contain any studies with human participants.

Conflict of interest Johannes Czernin is founder of Sofie Biosciences, which manufactures the Genisys4 scanner used in this manuscript. No other potential conflicts of interest are reported.

Author's contributions Initials: Stefano Boschi (SB), Jason T. Lee (JTL), Seval Beykan (SeB), Roger Slavik (RS), Liu Wei (LW), Uta Eberlein (UE), Andreas K. Buck (AKB), Filippo Lodi (FL), Gianfranco Coria (GC), Johannes Czernin (JC), Michael Lassmann (ML), Ken Herrmann (KH), Stefano Fanti (SF)

Conception and design: SB, AKB, JC, ML, KH, SF

Development of methodology: SB, JTL, RS, GC, ML, KH, SF

Acquisition of data: SB, JTL, RS, LW, FL, GC

Analysis and interpretation of data: JTL, SeB, RS, ML, KH, SF

Writing, review, and/or revision of the manuscript: all authors

Administrative, technical, or material support: SB, AKB, JC, ML, KH, SF

Supervision: SB, JC, ML, KH, SF

reaction time. After synthesis optimization, biodistribution and dosimetry studies were performed in C57BL6 mice. For proof of PSMA-specificity, mice were implanted with PSMA-negative (PC3) and PSMA-positive (LNCaP) tumors in contralateral flanks. Static and dynamic microPET/computed tomography (CT) imaging was performed.

Results—Quantitative labeling yields could be achieved with >97 % radiochemical purity. The ^{18}F -PSMA-11 uptake was more than 24-fold higher in PSMA-high LNCaP than in PSMA-low PC3 tumors (18.4 ± 3.3 %ID/g and 0.795 ± 0.260 %ID/g, respectively; $p < 4.2 \times 10^{-5}$). Results were confirmed by ex vivo gamma counter analysis of tissues after the last imaging time point. The highest absorbed dose was reported for the kidneys. The maximum effective dose for an administered activity of 200 MBq was 1.72 mSv.

Conclusion— ^{18}F -PSMA-11 using direct labeling of chelate-attached peptide with aluminum-fluoride detected PSMA-expressing tumors with high tumor-to-liver ratios. The kidneys were the dose-limiting organs. Even by applying the most stringent dosimetric calculations, injected activities of up to 0.56 GBq are feasible.

Keywords

PET; PSMA; ^{18}F ; Dosimetry; Preclinical; Prostate cancer

Introduction

Prostate-specific membrane antigen (PSMA) expression is associated with prostate cancer progression and prognosis [1]. PSMA-targeting positron emission tomography (PET) probes have become available for prostate cancer imaging [2–4]. Promising tracers include radiolabeled antibodies, aptamers, and small molecule inhibitors. Of these, ^{68}Ga -labeled PSMA-ligands have been extensively studied [5–15]. However, ^{68}Ga -labeled compounds are produced with generators that provide limited activity per synthesis. Thus, depending on the age of the generator, only 1–4 patient doses per elution can be produced. In contrast, much larger doses of ^{18}F -labeled tracers can be obtained by one cyclotron production. Thus, ^{18}F -compounds are suitable for off-site production and distribution over longer distances. As such, the introduction of ^{18}F -choline analogs for imaging prostate cancer [16] led to their widespread clinical use in Europe when compared to ^{11}C -choline [17].

Recent data suggest that radiolabeled PSMA ligands detect PSMA-expressing tumors with a higher sensitivity than choline derivatives. Moreover, a significant impact on patient management has been demonstrated [7]. Therefore, an urgent need exists to establish a straightforward method to label PSMA ligands with ^{18}F .

Previous methods to synthesize ^{18}F -labeled PSMA ligands have been successful [18–20]. However, these compounds are patented and not commonly accessible [18, 20], involve complex, multistep syntheses [18, 20], or haven't been investigated in preclinical models [19]. Development of direct labeling of peptides via aluminum-fluoride (Al^{18}F) chelation allows for a simple, not patented, and therefore freely accessible synthesis of ^{18}F -PSMA PET probes [19, 21–23].

The aims of this study were therefore (1) to establish the synthesis of an ^{18}F -PSMA tracer using direct labeling via Al^{18}F -chelation, and (2) to determine its in-vivo PSMA-specificity, biodistribution, and dosimetry in healthy and tumor-bearing mice. We chose the up-to-date most successful PSMA-targeted peptide tracer, PSMA-11. Complexed to natGa , the K_i value of PSMA-11 in a cell-based assay towards PSMA was determined to be 12.0 ± 2.8 nM and is readily taken up in PSMA-positive LNCaP cells.

Materials and methods

Synthesis development

Chemicals—Glu-urea-Lys (Ahx)-HBED-CC (PSMA-11) was purchased from ABX (Radeberg, Germany). $\text{AlCl}_3 \cdot 6\text{H}_2\text{O}$, sodium acetate trihydrate, and acetic acid were all metal-free. HPLC eluents, water, acetonitrile, and trifluoroacetic acid (TFA) were of high-grade purity. Sep-Pak Accell Plus QMA and Sep-Pak C18-Light cartridges were from Waters. No-carrier-added ^{18}F -fluoride was produced with the PETtrace cyclotron (GE Medical Systems, Uppsala) via an ^{18}O (p,n) ^{18}F reaction.

Preparation of ^{18}F -fluoride—QMA cartridge was conditioned with 5 mL of 0.5 M sodium acetate, followed by 10 mL of water (MilliQ, 18.5 M Ω). ^{18}F -fluoride solution was loaded onto the cartridge and after washing with 5 mL water, Na^{18}F was eluted by 200 μL of acetate buffer, pH 4.5 in one fraction (70–80 MBq), and by 300 μL into a second fraction (600–900 MBq).

Preparation of stock solutions—Sodium acetate/acetic acid buffer 0.5 M, pH 4.5 and 0.2 M, pH 6.3 were also prepared starting from 0.5 M solution of each component and mixing to obtain the desired final pH. PSMA-11 was dissolved in water [1 mg/500 μL] and aliquots were stored frozen (-18°C). $\text{AlCl}_3 \cdot 6\text{H}_2\text{O}$ 0.01 M was prepared in 0.05 M acetate buffer (pH 4) and stored at 4°C .

Synthesis of $[\text{Al}^{18}\text{F}]$ PSMA-11—For testing and optimizing the selected radiosynthesis parameters, 100 μL of Na^{18}F (200–300 MBq) solution from the second fraction was added to 3 μL of 0.01M $\text{AlCl}_3 \cdot 6\text{H}_2\text{O}$ (30nM) and 10–45 μL (20–90 μg) of PSMA-11. Acetate buffer and ethanol (30–200 μL) were finally added to a final reaction volume of 300 μL and the mixture was incubated at 50°C for 5–20 min. Aliquots of the mixture at different reaction time points were injected into high-performance liquid chromatography (HPLC) equipped with a reversed-phase column (Eclipse XDB-C8, 5 mm, 4.6×150 mm from Agilent (CA, USA) with isocratic elution (solvent A: 85 % water with 0.1 % TFA, solvent B: 15 % CH_3CN with 0.1%TFA) at a flow rate of 1 mL/min. HPLC was connected with a radiometric and UV detector set at 220 nm. The reaction mixture after incubation was trapped onto a Sep Pak C18 light cartridge, washed with saline, and eluted with 500 μL of ethanol. The final product was diluted with 3 mL of saline or acetate buffer 0.2 M pH 6.3 to verify the most suitable condition for stability. Quality control including absence of free fluoride for the final product was performed via radioHPLC. For animal experiments, an aliquot of the product solution containing 10 % ethanol was diluted with sterile saline. To check for stability, the reaction mixture after incubation was trapped onto a Sep Pak C18

light, the cartridge was washed with saline, and finally it was eluted with 500 μ L of ethanol and 3 mL of saline or acetate buffer 0.2 M at various pH values to verify the most suitable condition for stability.

Murine tumor models

Animal studies were approved by the UCLA Animal Research Committee and were carried out according to the guidelines of the Division of Laboratory Animal Medicine at UCLA. Six- to seven-week-old male C57BL6 mice were used to determine probe dosimetry. For tumor models, prostate cancer cell lines PC3 (PSMA-negative) and LNCaP (PSMA-positive), gifts from the laboratory of Robert Reiter at UCLA, were resuspended in 50 % phosphate-buffered saline and 50 % Matrigel™ (354234, BD Biosciences) and 1×10^6 cells each were injected subcutaneously on contralateral flanks of four male six- to seven-week-old NOD SCID gamma-null (NSG) mice.

In-vitro stability assay

The in-vitro stability of ^{18}F -PSMA-11 (20 μ L) was determined in mouse and human blood plasma (180 μ L) at 37 °C at time points 30, 60, 90, and 120 min. At each time point, an aliquot of 50 μ L of the incubation mixture was collected, treated with 50 μ L ice-cooled MeCN, centrifuged, and the supernatant was analyzed by thin-layer radiochromatography (radio-TLC). Results have been confirmed by radio-HPLC.

Animal PET/CT image acquisition and analysis

C57BL6 and tumor-bearing NSG mice, engrafted with tumor cells approximately 2 weeks prior, underwent ^{18}F -PSMA and ^{18}F -FDG microPET/computed tomography (CT) imaging (GENISYS 8 PET/CT, Sofie Biosciences). The G8 PET/CT is an integrated scanner with a PET subsection optimized for mouse imaging with an energy window of 150–650 keV and peak sensitivity of approximately 14 % at the center of FOV. The intrinsic detector spatial resolution is 1.5 mm full-width at half-maximum (FWHM) in the transverse and axial directions.

The CT section consists of a gantry and flywheel that uses a 50 kVp, 200 μ A x-ray source and flat-panel detector. The CT acquires images in a continuous-rotation mode with 720 projections at 55 msec per projection, and reconstructed using a Feldkamp algorithm.

Mice were anesthetized under 2 % isoflurane, placed in a heated G8 imaging chamber and catheterized by the tail vein. The chamber was placed in the PET section of the G8. PET data were acquired at 0–1 h (dynamic), 2 h, 4 h and 6 h after bolus ^{18}F -PSMA-11 injection (approximately 1.4 MBq, 0.21 nmol). Animals were conscious and kept warm in between imaging time points. For ^{18}F -FDG, mice were fasted overnight, followed by intravenous injection of ^{18}F -FDG (approximately 1.4 MBq) and PET/CT imaging after 1 h unconscious uptake. The list-mode data-framing sequence for the 0–1 h dynamic scan was 1×10 s, 4×15 s, 8×30 s, 5×60 s, 4×300 s, 3×600 s.

Maximum-likelihood expectation maximization was used to create the final image volumes as recommended by the vendor. All images were corrected for photon attenuation. Images

were analyzed using AMIDE version 1.0.5 [24] and OsiriX version 3.8 imaging software. Images were quantified using 2-mm diameter regions-of-interest (ROI) except for kidneys, bladder, and whole body, which were determined using 3D isocontours, and reported in Bq/mL.

Biodistribution analysis

^{18}F -PSMA-11 biodistribution in wild-type C57BL6 mice was determined by microPET/CT imaging as described and confirmed by ex-vivo analysis. For the latter, each mouse was sacrificed following its last PET imaging. Tissues were collected, weighed, and radioactivity counted on a Packard Cobra II Auto Gamma Counter with decay correction to time of ^{18}F -PSMA-11 injection. Data were normalized to mass of tissue.

Dosimetry analysis

From quantitative ^{18}F -PSMA-11 microPET scans of male C57BL6 mice, the amount of activity in selected organs was quantified and absorbed doses were calculated based on the respective time-integrated activity coefficients. The dose extrapolation to humans involved the scaling of the biodistributions and the subsequent calculation of the absorbed doses from them. The biodistribution scaling was performed by two alternative methods. Method 1 was based on the assumption that the residence time for the same organ is the same in mice and humans [25, 26]. Method 2 considered a relative mass scaling where the specific activity in a certain human organ is equal to the specific activity in the same mouse organ multiplied by the ratio of the body mass of human and mouse [25, 27, 28]. Time-integrated activity coefficients (TIACs or “Residence Times”, RT) were calculated with using the software solution NUKFIT as described by Kletting et al., choosing the optimal fit functions as proposed by the code [29]. The dose calculation was performed for a selected group of organs using OLINDA/EXM V1.1 [30]. Details on the methodology used for extrapolating the mouse data to humans are provided in the supplementary information.

Statistical analysis

Data are presented as mean $\pm$ standard deviation. All p values were determined with unpaired, two-tailed T tests, and values less than 0.05 were considered to be statistically significant. GraphPad Prism 6 and Origin 2015 software were used to calculate statistics and generate graphs.

Results

Radioligand synthesis

During the synthesis setup, samples were taken at 5, 10, 15, and 20 min. In most conditions, no changes after 10 min of reaction time were observed. The presence of ethanol dramatically increased the percentage of Al^{18}F binding to the peptide (Fig. 1). In the absence of ethanol, approximately 30 % of the labeling was obtained at 100 °C with 90 μg of peptide. Increasing the ethanol concentration (from 0 to 60 %) allowed higher binding

Electronic supplementary material The online version of this article (doi:10.1007/s00259-016-3437-y) contains supplementary material, which is available to authorized users.

values also in the presence of less peptide amount and lower temperature (50 °C). After incubating 20 µg of peptide in the presence of 150–180 µL (50–60 %) of ethanol, 70–90 % of binding was obtained, with a slight decrease using 200 µL (67 %) of ethanol. A typical chromatogram of the reaction mixture is shown in Fig. 2. An increase of Al³⁺ concentration from 0.10 to 0.33 nmol/µL led to a decrease of labeling efficiency to approximately 50 % (data not shown). The stability was confirmed in a 3 h stability test. The results showed that radiochemical purity > 97 % was observed in buffered solution at pH 6.8 in comparison with un-buffered saline formulation, which showed a roughly 20 % decrease in radiochemical purity after 3 h.

For the final PET imaging studies, aliquoted 25 µg precursor, 3 µL AlCl₃ (0.01 M), 260–740 MBq Na¹⁸F (100 µL), and 150 µL ethanol were mixed and incubated for 10 min at 50 °C on a shaking plate. After purification of [Al¹⁸F] PSMA-11 over a C18 Sep Pak light, the product was eluted with 0.5 mL ethanol and diluted with 4.5 mL acetate buffer (0.2 M, pH 6.8). The product solution was filtered through a sterile filter into the final product vial, yielding a radiochemical purity of >99 % with a specific activity of at least >9.9 GBq/µmol. The final product was stable in mouse and human plasma for a time course of up to 2 h with 91 and 94% intact compound, respectively.

Biodistribution

The highest ¹⁸F-PSMA-11 tissue uptake at 1 h post-injection by microPET imaging was in the kidneys in all mice (119.3 ± 16.5 %ID/g) and bladder (77.4 ± 39.1 %ID/g) (Fig. 3). All other tissues exhibited relatively low uptake. Results were confirmed by ex-vivo tissue analysis.

Time activity curves derived from PET imaging demonstrated fast uptake and retention in kidneys, minimal retention in bone, wash-out from other tissues (linear decline on logarithmic plot), and rapid renal clearance as indicated by significant bladder activity.

Tumor imaging

¹⁸F-PSMA-11 uptake was significantly higher in PSMA-high LNCaP (Fig. 3) than in PSMA-low PC3 tumors (55.7 ± 11.8 %ID/g and 3.1 ± 0.9 %ID/g, respectively; $p < 3.6 \times 10^{-4}$). Time-activity curves derived from PET imaging showed early ¹⁸F-PSMA-11 saturation in LNCaP tumors. Probe uptake was 24 times higher in LNCaP than in PC3 tumors. Time-activity curves in PC3 tumors were nearly identical to those for background tissues such as muscle and liver, and were in general only 1–2 times higher. Results were confirmed with ex-vivo gamma counter analysis of tissues after the last imaging time point. In contrast, ¹⁸F-FDG uptake only tended to differ between LNCaP and PC3 tumors (3.1 ± 0.6 %ID/g and 4.2 ± 0.7 %ID/g, respectively; $p = 0.07$).

Dosimetric calculations

Absorbed doses for ¹⁸F-PSMA-11 in humans were extrapolated from mouse PET biodistribution data using two extrapolation methods, method 1 and method 2 (see supplemental file). The time-integrated activity coefficients (TIACs) are summarized in Table 1. A full list of the corresponding mean absorbed doses is provided in Table 2.

The highest TIAC was observed for the kidneys and bone based on method 1 (mean RTkidney: 0.141 ± 0.033 h, mean RTbone: 0.045 ± 0.013 h). Based on method 2, the highest TIACs were observed for the bone, muscle, and kidneys (mean RTbone: 0.114 ± 0.028 h, mean RTmuscle: 0.077 ± 0.018 h, and mean RTkidney: 0.042 ± 0.009 h). The total absorbed doses are summarized in Table 2. The highest absorbed dose was 8.87×10^{-2} mGy/MBq and 2.87×10^{-2} mGy/MBq for the kidneys in method 1 and method 2, respectively. All other organs showed significantly lower absorbed doses (Fig. 4). Kidneys were the dose-limiting organ, and on average, the maximum administered human activity limit is calculated to be 564 MBq (Method 1) and 1,742 MBq (Method 2) (FDA Code of Federal Regulations 21CFR361.1). In addition, the effective dose per unit activity was calculated. However, the quantity “effective dose” can only be applied to the description of stochastic radiation effects and organ-absorbed doses of less than 1 Gy. The mean extrapolated effective doses are $8.59 \times 10^{-3} \pm 7.46 \times 10^{-4}$ mSv/MBq (Method 1) and $6.23 \times 10^{-3} \pm 5.74 \times 10^{-4}$ mSv/MBq (Method 1). This corresponds to effective doses of 1.72 mSv (Method 1) and 1.25 mSv (Method 2) for an administered activity of 200 MBq.

Discussion

Here we report the successful synthesis of ^{18}F -PSMA-11 via Al^{18}F -complexation. High radiochemical purity was achieved and the tracer was stable in mouse and human plasma with 91 and 94 % intact compound after 2 h incubation at 37 °C. Specificity for PSMA was confirmed by the significantly higher uptake in PSMA-positive relative to PSMA-negative xenografts. In contrast, ^{18}F -FDG verified tissue viability, but was not able to reliably differentiate between the two tumor types. Biodistribution and dosimetry studies identified the kidneys as the critical organ. The most conservative calculations would permit human administration of up to 564 MBq. This results in much lower effective doses than those associated with other clinically available PSMA-targeting PET probes. However, results acquired in mice can only be extrapolated to humans with caution.

In contrast to other promising ^{18}F -labeled PSMA-directed compounds [31, 32] ^{18}F -PSMA-11 will be freely accessible, as this ligand is developed without commercial interest. Especially in Europe, Asia, and South America where the radiopharmaceutical is very often not adequately reimbursed, this may be of major importance and a significant driver for clinical adoption.

Moreover, the synthesis of ^{18}F -PSMA-11 is a very simple one-pot, one-step synthesis following the recently published findings by Malik et al [19]. The simplicity is beneficial compared to the more complex multistep syntheses of ^{18}F -DCFBX [20] and ^{18}F -DCFPyL [18].

We found ethanol to strongly influence labeling efficiency and achieved the highest yield with 60 % ethanol in the reaction mixture. This is because ethanol and other polar solvents like acetonitrile and isopropanol facilitate the binding by breaking the hydration sphere of the metal in solution.

Biodistribution of ^{18}F -PSMA-11 by microPET imaging of non-tumor-bearing C57BL6 mice demonstrated fast renal clearance as confirmed by kidney and bladder uptake within the first hour of probe administration. At later time points the kidney signal arises from the renal cortex, which is not unexpected since PSMA is expressed in renal tubules [33]. Bone uptake was at least one order of magnitude lower than kidney uptake, as confirmed by ex-vivo analysis of femur bone versus bone marrow. This suggests a minimal degree of defluorination of ^{18}F -PSMA-11, as PSMA is only expressed in renal tubules, prostate epithelium, and some intestinal tissues [33] but not in the bone. Whether this will affect human image quality and diagnostic information has yet to be determined.

The high ^{18}F -PSMA-11 uptake in LNCaP and low uptake in PC3 tumors is explained by the high and low PSMA expression of the corresponding tumors [3, 34]. Both xenografts demonstrated ^{18}F -FDG avidity, confirming viable tumor tissue and further supporting the target selectivity of ^{18}F -PSMA-11. The tendency towards higher ^{18}F -FDG uptake values in the PC3 cells most likely reflects the previously published higher aggressiveness and shorter doubling time [35] compared to LNCaP [36].

The favorable biodistribution resulted an estimated maximum effective dose of 1.7 mSv for an injection of 200 MBq ^{18}F -PSMA-11. Thus, the radiation dose is significantly lower than of currently used ^{18}F - and ^{68}Ga -labeled compounds [32, 37].

The substantially higher prostate cancer detection rates of ^{68}Ga -PSMA compared to the established ^{18}F -choline [7, 38] has already resulted in its rapid clinical acceptance in Europe. The favorable biodistribution and dosimetry, the reliable and simple synthesis and the high PSMA selectivity of ^{18}F -PSMA-11 via Al^{18}F -complexation underline the high translational potential of this compound. No safety concerns arise from the use of aluminum chloride in the PET drug preparation, although aluminum is considered to have neurotoxic effects at higher doses. Normal serum aluminum concentration is measured to be $0.1\text{ }\mu\text{mol/L}$ [39]. Our synthesis starts with $0.03\text{ }\mu\text{mol AlCl}_3$, whereas most is washed out during the C18 cartridge purification step.

As the availability of ^{68}Ga -labeled PSMA ligands is limited due to the shorter half-life and the generator size-dependent product output, there is a need for cyclotron-produced PSMA PET tracers such as ^{18}F -PSMA-11. Despite a minimal amount of defluorination, the preclinical results strongly suggest that the clinical translation of ^{18}F -PSMA-11 is feasible and warranted. Future studies comparing ^{18}F -PSMA-11 with ^{68}Ga -PSMA-11, ^{18}F -DCFBX, and ^{18}F -DCPyL are mandatory to elucidate which of the currently available compounds provides superior specific activities, biodistribution, and tumor-to-background ratios.

Conclusion

The clinical need for early detection of prostate cancer in patients with biochemical recurrence and the selectivity of PSMA ligands drive their development and translation. Synthesis of ^{18}F -PSMA-11 by direct-labeling of chelate-attached-peptides with aluminum fluoride provides high radiochemical purity and product yields.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Larry Pang and Andreea Stuparu (members of the Ahmanson Translational Imaging Division) for their support and assistance.

Funding This study was partly supported by an unrestricted grant from the Movember Foundation—MOVEMBER GAP2 FUNDING AWARD.

References

1. Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. *J Cell Biochem*. 2004; 91:528–539. [PubMed: 14755683]
2. Eder M, Schafer M, Bauder-Wust U, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. *Bioconjug Chem*. 2012; 23:688–697. [PubMed: 22369515]
3. Weineisen M, Schottelius M, Simecek J, et al. 68Ga- and 177Lu-labeled PSMA I&T: optimization of a PSMA targeted theranostic concept and first proof of concept human studies. *J Nucl Med*. 2015
4. Mease RC, Foss CA, Pomper MG. PET imaging in prostate cancer: focus on prostate-specific membrane antigen. *Curr Top Med Chem*. 2013; 13:951–962. [PubMed: 23590171]
5. Schiavina R, Ceci F, Romagnoli D, et al. Ga-PSMA-PET/CT-guided salvage retroperitoneal lymph node dissection for disease relapse after radical prostatectomy for prostate cancer. *Clin Genitourin Cancer*. 2015
6. Budaus L, Leyh-Bannurah SR, Salomon G, et al. Initial experience of Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. *Eur Urol*. 2015
7. Morigi JJ, Stricker PD, van Leeuwen PJ, et al. Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. *J Nucl Med*. 2015; 56:1185–1190. [PubMed: 26112024]
8. Jadvar H. PSMA PET, in prostate cancer. *J Nucl Med*. 2015; 56:1131–1132. [PubMed: 25977465]
9. Ceci F, Uprimny C, Nilica B, et al. (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? *Eur J Nucl Med Mol Imaging*. 2015; 42:1284–1294. [PubMed: 25975367]
10. Eiber M, Maurer T, Souvatzoglou M, et al. Evaluation of hybrid (6)(8)Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. *J Nucl Med*. 2015; 56:668–674. [PubMed: 25791990]
11. Kabasakal L, Demirci E, Ocak M, et al. Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging. *Nucl Med Commun*. 2015; 36:582–587. [PubMed: 25738559]
12. Chakraborty PS, Kumar R, Tripathi M, Das CJ, Bal C. Detection of brain metastasis with 68Ga-labeled PSMA ligand PET/CT: a novel radiotracer for imaging of prostate carcinoma. *Clin Nucl Med*. 2015; 40:328–329. [PubMed: 25674861]
13. Avanesov M, Karul M, Derlin T. (68)Ga-PSMA as a new tracer for evaluation of prostate cancer: comparison between PET-CT and PET-MRI in biochemical recurrence. *Radiologe*. 2015; 55:89–91. [PubMed: 25583413]
14. Afshar-Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. *Eur J Nucl Med Mol Imaging*. 2015; 42:197–209. [PubMed: 25411132]
15. Uprimny C, Kroiss A, Nilica B, et al. (68)Ga-PSMA ligand PET versus (18)F-NaF PET: evaluation of response to (223)Ra therapy in a prostate cancer patient. *Eur J Nucl Med Mol Imaging*. 2015; 42:362–363. [PubMed: 25293866]

16. Iwata R, Pascali C, Bogni A, Furumoto S, Terasaki K, Yanai K. [18F]fluoromethyl triflate, a novel and reactive [18F]fluoromethylating agent: preparation and application to the on-column preparation of [18F]fluorocholine. *Appl Radiat Isot.* 2002; 57:347–352. [PubMed: 12201141]
17. Evangelista L, Cervino AR, Guttilla A, Zattoni F, Cuccurullo V, Mansi L. (1)(8)F-fluoromethylcholine or (1)(8)F-fluoroethylcholine pet for prostate cancer imaging: which is better? a literature revision. *Nucl Med Biol.* 2015; 42:340–348. [PubMed: 25618796]
18. Chen Y, Pullambhatla M, Foss CA, et al. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. *Clin Cancer Res.* 2011; 17:7645–7653. [PubMed: 22042970]
19. Malik N, Baur B, Winter G, Reske SN, Beer AJ, Solbach C. Radiofluorination of PSMA-HBED via AlF chelation and biological evaluations in vitro. *Mol Imaging Biol.* 2015
20. Mease RC, Dusich CL, Foss CA, et al. N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer. *Clin Cancer Res.* 2008; 14:3036–3043. [PubMed: 18483369]
21. McBride WJ, Sharkey RM, Goldenberg DM. Radiofluorination using aluminum-fluoride (Al18F). *EJNMMI Res.* 2013; 3:36. [PubMed: 23651690]
22. McBride WJ, D'Souza CA, Karacay H, Sharkey RM, Goldenberg DM. New lyophilized kit for rapid radiofluorination of peptides. *Bioconjug Chem.* 2012; 23:538–547. [PubMed: 22273147]
23. D'Souza CA, McBride WJ, Sharkey RM, Todaro LJ, Goldenberg DM. High-yielding aqueous 18F-labeling of peptides via Al18F chelation. *Bioconjug Chem.* 2011; 22:1793–1803. [PubMed: 21805975]
24. Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. *Mol Imaging.* 2003; 2:131–137. [PubMed: 14649056]
25. Repetto-Llamazares AH, Larsen RH, Mollatt C, Lassmann M, Dahle J. Biodistribution and dosimetry of (177)Lu-tetulumab, a new radioimmunoconjugate for treatment of non-Hodgkin lymphoma. *Curr Radiopharm.* 2013; 6:20–27. [PubMed: 23256748]
26. Sparks, RB.; Aydogan, B. Comparison of the effectiveness of some common animal data scaling techniques in estimating human radiation dose. In: Stelson, A.; Stabin, M.; Sparks, R., editors. *Sixth International Radiopharmaceutical Dosimetry Symposium*; 1999. p. 705-716.
27. International Commission on Radiological Protection (ICRP). Publication 89: basic anatomical and physiological data for use in radiological protection—reference values. *Ann ICRP.* 2002; 32:1–278.
28. Bitar A, Lisbona A, Thedrez P, et al. A voxel-based mouse for internal dose calculations using Monte Carlo simulations (MCNP). *Phys Med Biol.* 2007; 52:1013–1025. [PubMed: 17264367]
29. Kletting P, Schimmel S, Kestler HA, et al. Molecular radiotherapy: the NUKFIT software for calculating the time-integrated activity coefficient. *Med Phys.* 2013; 40:102504. [PubMed: 24089925]
30. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. *J Nucl Med.* 2005; 46:1023–1027. [PubMed: 15937315]
31. Dietlein M, Kobe C, Kuhnert G, et al. Comparison of [F]DCFPyL and [Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. *Mol Imaging Biol.* 2015
32. Szabo Z, Mena E, Rowe SP, et al. Initial evaluation of [F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. *Mol Imaging Biol.* 2015
33. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. *Clin Cancer Res.* 1997; 3:81–85. [PubMed: 9815541]
34. Fuchs AV, Tse BW, Pearce AK, et al. Evaluation of polymeric nanomedicines targeted to PSMA: effect of ligand on targeting efficiency. *Biomacromolecules.* 2015; 16:3235–3247. [PubMed: 26335533]
35. Kochuparambil ST, Al-Husein B, Goc A, Soliman S, Somanath PR. Anticancer efficacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of Akt and reduced prostate-specific antigen expression. *J Pharmacol Exp Ther.* 2011; 336:496–505. [PubMed: 21059805]

36. Horoszewicz JS, Leong SS, Kawinski E, et al. LNCaP model of human prostatic carcinoma. *Cancer Res.* 1983; 43:1809–1818. [PubMed: 6831420]
37. Afshar-Oromieh A, Hetzheim H, Kratochwil C, et al. The novel theranostic PSMA-ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry and first evaluation of tumor lesions. *J Nucl Med.* 2015
38. Afshar-Oromieh A, Zechmann CM, Malcher A, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. *Eur J Nucl Med Mol Imaging.* 2014; 41:11–20. [PubMed: 24072344]
39. Lavergne V, Ghannoum M, Christie M, et al. Risk factors and consequences of hyperalbuminemia in a peritoneal dialysis cohort. *Perit Dial Int.* 2012; 32:645–651. [PubMed: 22855887]

Fig. 1.

Percentage of Al¹⁸F binding to PSMA-11 in various reaction conditions. Red line demonstrates the decrease of peptide concentration as a function of the ethanol concentration

Fig. 2.

Radio-HPLC chromatogram of the reaction product in the chromatographic condition (20 μg of peptide, 60 % ethanol, 50 $^{\circ}\text{C}$, shaking). First peak confirmed as $\text{Al}^{18}\text{F}^{2+}$ (data not shown), second peak assigned via retention time comparison with DKFZ-PSMA-11

Fig. 3. MicroPET/CT imaging. **a** Volume rendering and tissue biodistribution of ^{18}F -PSMA-11 in C57BL6. **b** Volume rendering of ^{18}F -PSMA-11 and **c** MIP image of ^{18}F -FDG in NSG mice engrafted with PC3 (*right*) and LNCaP (*left*) tumor cells. Shown are representative microPET/CT images 1 h post-injection of PET probe. Error bars are standard deviations. Tumors are delineated in dashed circles

Fig. 4.
Non-decay-corrected time activity curves determined by microPET imaging and accounting for total organ weights

Table 1

The mean time-integrated activity coefficient (RT) values for the several organs scaled to humans

Target Organs	Mean RT		Mean Standard Deviations	
	Method 1	Method 2	Method 1	Method 2
Brain	2.30E-03	2.70E-03	4.90E-04	5.50E-04
Stomach	5.90E-03	6.70E-04	1.80E-03	2.80E-04
Heart content	1.70E-02	1.70E-02	3.90E-03	4.00E-03
Heart wall	1.90E-03	1.30E-03	4.40E-04	2.20E-04
Tot. Kidney	1.40E-01	4.20E-02	3.30E-02	9.40E-03
Liver	1.30E-02	7.30E-03	4.60E-03	2.30E-03
Lung	3.30E-03	5.60E-03	1.20E-03	1.30E-03
Muscle	8.30E-04	7.70E-02	2.30E-04	1.80E-02
Bone marrow	1.70E-04	2.10E-04	3.80E-05	4.10E-05
Cortical bone	3.00E-02	7.70E-02	8.50E-03	1.80E-02
Trab. Bone	1.50E-02	3.80E-02	4.20E-03	9.10E-03
Spleen	1.70E-03	2.30E-03	9.50E-04	1.20E-03
Bone	4.50E-02	1.10E-01	1.30E-02	2.80E-02
Bladder	3.10E-02	—	1.40E-02	—
Remainder WB	9.70E-01	9.70E-01	8.70E-02	8.70E-02

Table 2

The mean absorbed dose coefficient values to the organs and the respective standard deviations for both methods

Target Organ	Mean Absorbed Dose Coefficients of the Organs (mGy/MBq)		Mean Standard Deviations	
	Method 1	Method 2	Method 1	Method 2
Adrenals	8.0E-03	6.5E-03	9.3E-04	5.9E-04
Brain	1.5E-03	1.9E-03	1.2E-04	1.2E-04
Breasts	4.8E-03	4.9E-03	3.9E-04	4.0E-04
Gallbladder Wall	7.5E-03	6.6E-03	7.8E-04	6.2E-04
LLI Wall	6.9E-03	6.8E-03	4.4E-04	5.9E-04
Small Intestine	7.9E-03	7.5E-03	6.6E-04	6.6E-04
Stomach Wall	8.5E-03	6.2E-03	1.1E-03	6.1E-04
ULI Wall	7.6E-03	7.2E-03	6.5E-04	6.4E-04
Heart Wall	7.4E-03	7.2E-03	1.1E-03	8.4E-04
Kidneys	8.9E-02	2.9E-02	2.0E-02	6.0E-03
Liver	4.7E-03	3.5E-03	8.2E-04	4.8E-04
Lungs	3.3E-03	3.8E-03	4.0E-04	3.8E-04
Muscle	3.4E-03	3.7E-03	2.5E-04	3.2E-04
Ovaries	7.1E-03	6.9E-03	4.7E-04	6.1E-04
Pancreas	7.9E-03	6.8E-03	8.3E-04	6.3E-04
Red Marrow	5.6E-03	6.4E-03	3.5E-04	5.7E-04
Osteogenic Cells	1.0E-02	1.5E-02	8.9E-04	1.8E-03
Skin	4.1E-03	4.2E-03	3.4E-04	3.5E-04
Spleen	6.7E-03	5.6E-03	1.2E-03	1.4E-03
Testes	5.4E-03	5.5E-03	3.6E-04	4.8E-04
Thymus	5.3E-03	5.6E-03	3.7E-04	3.9E-04
Thyroid	5.1E-03	5.5E-03	4.3E-04	4.6E-04
Urinary Bladder Wall	2.1E-02	6.7E-03	8.1E-03	5.8E-04
Uterus	7.8E-03	7.2E-03	4.7E-04	6.3E-04
Total Body	5.7E-03	5.7E-03	4.6E-04	4.7E-04